A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder.
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Biomarker
- 07 Jun 2017 Biomarkers information updated
- 12 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.